Algernon Pharmaceuticals reports positive pre-clinical data on DMT candidate to treat stroke

The drug-repurposing firm is researching AP-188 (N,N-Dimethyltryptamine, or DMT), a psychedelic compound, as a potential treatment for the rehabilitation of stroke.